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Abstract 59	
Equine piroplasmosis (EP) has historically been of minor concern to UK equine 60	
practitioners, primarily due to a lack of competent tick vectors. However, increased 61	
detection of EP tick vector species in the UK has been reported recently. EP screening 62	
is not currently required for equine importation, and when combined with recent 63	
relaxations in movement regulations, there is an increased risk regarding disease 64	
incursion and establishment into the UK. 65	
This study evaluated the prevalence of EP by both serology and polymerase chain 66	
reaction (PCR) among 1,242 UK equine samples submitted for EP screening between 67	
February and December 2016 to the Animal and Plant Health Agency and the Animal 68	
Health Trust. Where information was available, 81.5 % of submissions were for the 69	
purpose of UK export testing, and less than 0.1 % for UK importation. Serological 70	
prevalence of EP was 8.0 %, and parasite DNA was found in 0.8 % of samples. 71	
A subsequent analysis of PCR sensitivity in archived clinical samples indicated that 72	
the proportion of PCR-positive animals is likely to be considerably higher. We 73	
conclude the current threat imposed by UK carrier horses is not adequately monitored 74	
and further measures are required to improve national biosecurity and prevent 75	
endemic disease.  76	
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Introduction 77	
The UK has historically remained free from endemic equine piroplasmosis (EP), 78	
despite a near ubiquitous global presence (1). Consequently, the disease has been of 79	
minimal concern to the UK equine practitioner and diagnostic testing has not been 80	
undertaken routinely, even in horses presenting with classical clinical signs such as 81	
haemolytic anaemia. 82	
The basic pathology of EP together with the life-cycle of its causative pathogens, 83	
Theileria equi and Babesia caballi, are well described in the literature (1, 2, 3). 84	
Following inoculation by an infected tick vector, the protozoan parasite invades host 85	
erythrocytes, with additional invasion of host leukocytes in the case of T. equi. The 86	
parasite replicates in the equine erythrocytes leading to rupture of the infected cell. 87	
This releases parasite merozoites into the circulation, which further invade and 88	
replicate within erythrocytes, perpetuating the infection. Within the tick host, 89	
transmission of T. equi is through the transtadial route, while for B. caballi transtadial 90	
and transovarian transmission both occur (3). The clinical presentation of infection 91	
with one or both of these parasites is similar. Acute cases typically present with 92	
anaemia, pyrexia, lethargy, dehydration and anorexia with death occurring in severe 93	
or neglected cases (1, 2, 3). In chronic disease, clinical signs are less severe, with 94	
animals displaying variable anaemia, malaise, anorexia, weight loss and reduced 95	
performance (1, 2, 3). Infection with T. equi has been detrimentally associated with 96	
athletic performance (4) and has a significant impact on the racing industry of 97	
endemic areas (5). An association also has been claimed between EP and reduced 98	
fertility and abortion, with a reported 11 % of South African thoroughbred abortions 99	
being attributed to T. equi infection (6). 100	
Importantly, the insidious nature of chronic and subclinical forms of the disease can 101	
lead to the creation of a latent carrier state that is particularly common in endemic 102	
regions. This has important implications for biosecurity. It is reported that B. caballi 103	
carrier status is self-limiting with clearance achieved four years post-infection (7), but 104	
this may be due to infection entering a latent stage (1). Clearance of B. caballi 105	
infection can been achieved through treatment with imidocarb dipropionate (8). 106	
Theileria equi carrier status is thought to be life-long and can be maintained despite 107	
medical treatment (9). The unmonitored importation of these carrier animals to 108	
different regions of the UK, compounded by a lack of tick control and prolonged co-109	
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grazing and mixing with naïve individuals, presents a potential means by which the 110	
infection could become established in the UK. 111	
Although EP seropositive equids have been imported and present in the UK for many 112	
years, the lack of endemic EP in the British Isles has historically been attributed to a 113	
small and geographically limited vector tick population (10). Up to 33 tick species 114	
have been identified as known or potential vectors for EP (11), but Dermacentor 115	
reticulatus is the only confirmed EP vector species currently established in the UK. 116	
Dermacentor reticulatus populations were thought to be limited to areas in western 117	
Wales and Devon, however recent studies have documented geographical expansion 118	
of the species, with recognised populations now present in Essex (12). The 119	
epidemiological importance of these new D. reticulatus vector populations in the 120	
transmission of tick-borne disease was highlighted in a recent canine piroplasmosis 121	
outbreak in the Essex area (13). 122	
EP has also been moving geographically closer to the UK in recent years, with an 123	
isolated T. equi outbreak in Ireland in 2009 (14), autochthonous cases of both T. equi 124	
and B. caballi reported in Holland in 2011 (15) and evidence of both parasites being 125	
well established in the Camargue of France (16). When combined with current 126	
policies mitigating restrictions of certain equine movements, such as the Tripartite 127	
Agreement of 2014 (17) and the proposed High Health High Performance (HHP) 128	
scheme (18), the threat of EP to the resident UK horse population is becoming of 129	
increasing concern. 130	
The latest World Organisation for Animal Health (OIE) status of EP in the UK (July - 131	
December 2017) is ‘infection/infestation in domestic animals’, and ‘disease absent in 132	
wild animals’ (19). This reflects the presence of imported EP seropositive equids, 133	
with the absence of any autochthonous cases of endemic disease. 134	
Currently EP is not reportable or notifiable in the UK and imported animals are not 135	
tested routinely, despite the fact that seropositive chronic carrier horses are known to 136	
act as reservoirs of parasite infection for suitable sympatric tick species if present 137	
(20). Serological testing in the UK is largely restricted to animals being exported to 138	
disease-free countries with compulsory import screening, such as USA, Australia and 139	
Japan, where the disease is notifiable and controlled. 140	
It is useful to consider the diagnostic tests presently available for EP screening. 141	
Current OIE guidelines recommend the indirect fluorescent antibody test (IFAT) and 142	
the competitive enzyme-linked immunosorbent assay (cELISA) as the screening tests 143	
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for international trade (21), and the older complement fixation test (CFT) is still 144	
available and utilised commercially. Although sensitive, serological testing such as 145	
the cELISA does not reflect level of parasitaemia or provide information on the 146	
likelihood of onward transmission to feeding ticks, since antibodies persist for many 147	
months after apparent clearance of infection (22). Polymerase chain reaction (PCR) 148	
methods and, specifically, nested PCR are considered to be the best means of 149	
establishing parasite burden in equids (3). Despite the description of many PCR 150	
protocols in the literature, a commercial PCR screening assay for EP is not readily 151	
available to UK practitioners. 152	
The main aim of this pilot study was to investigate the potential risk posed by 153	
seropositive horses resident in the UK, using follow-up nested PCR to determine 154	
animals with a parasite burden. A nested PCR protocol was developed and validated 155	
in-house using known positive field specimens. Results from UK diagnostic 156	
submissions for EP serology were also collated to facilitate estimation of the 157	
proportion of this sampled population that was serologically and PCR positive, 158	
therefore presenting a potential transmission risk to feeding tick species. 159	
 160	
Materials and methods 161	
This prospective study utilised routine samples submitted by UK practitioners for EP 162	
serology testing at the Animal and Plant Health Agency (APHA) and the Animal 163	
Health Trust (AHT), between February and December 2016. Serological testing 164	
performed comprised CFT, IFAT and cELISA either singularly or in combination as 165	
requested by the submitting veterinary surgeon. The CFT, which was only available at 166	
the APHA, was performed in accordance with OIE standards using an in-house 167	
protocol. The APHA also performed IFAT assays using an in-house protocol in 168	
accordance with OIE standards; titres ≥ 1/80 were reported as positive. IFATs 169	
requested on AHT submitted samples were performed at the APHA, although the 170	
results have been associated with the AHT for data consistency (Table 1). For 171	
cELISA testing, both the AHT and APHA used commercially available kits (Babesia 172	
caballi 273-2 and Babesia equi 274-2, VMRD, USA), with a result of ≥ 40 % 173	
reported as positive. 174	
Following EP serological screening, all samples from both institutes were then 175	
forwarded to the University of Glasgow as anonymised clotted equine blood samples. 176	
They were then subjected to nested PCR, allowing subsequent comparison to the 177	
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serological test results supplied by each laboratory. As the samples were submitted for 178	
the primary purpose of serology testing, only clotted blood was available for PCR 179	
screening. 180	
For DNA extraction, 200 µl of clotted blood was mechanically agitated then 181	
enzymatically digested with proteinase K prior to extraction with the QIAamp DNA 182	
Mini Kit (Qiagen), using the manufacturer’s recommended protocol. A total of 1,211 183	
samples were screened by nested PCR with a modified Babesia/Theileria 18S SSU 184	
rRNA catch-all primer set, with outer primers (23) and inner primers (24) as 185	
described previously. These primers were reported to effectively detect a range of 186	
Theileria/Babesia spp., including T. equi and B. caballi (23). Prior to sample 187	
screening, the reaction conditions were optimised in-house with known EP positive 188	
samples from Morocco, Gambia and Oman. Reaction conditions were an initial 189	
denaturation at 94 °C for 5 minutes, followed by 30 cycles of 94 °C for 45s, with 190	
annealing at 67 °C (external primers) or 57 °C (internal primers) for 60s, elongation at 191	
72 °C for 60s, and with a final extension at 72 °C for 5 minutes. A 1:10 dilution of the 192	
primary reaction product was used as a template for the secondary reaction. The final 193	
product was visualised on a 1 % agarose electrophoresis gel. The PCR product was 194	
purified (QIAquick PCR purification kit, Qiagen) prior to Sanger DNA sequencing 195	
(Eurofins Genomics, Germany). 196	
Sequences were subject to BLAST comparison (https://blast.ncbi.nlm.nih.gov/) with 197	
the non-redundant NCBI database to achieve species identification. 198	
In each case, the result of the nested PCR was then compared to the EP serological 199	
test result as supplied by the original laboratory. Although all data were anonymised, 200	
and information about sampled animals was unavailable, the reason for EP serological 201	
test submission was known for the majority of specimens. Additionally, an acute case 202	
of piroplasmosis was confirmed during the study period, seen in a horse previously 203	
imported but now resident in the UK. Samples from this horse were used to compare 204	
the effect of coagulated and anti-coagulated blood samples on nested PCR 205	
performance. 206	
 207	
Results 208	
Serological test results and nested PCR results from the full 1, 242 UK laboratory EP 209	
submissions are presented in Table 1. In summary, 5.9 % of samples submitted during 210	
the study period were serologically positive for T. equi (n = 70), and 4.4 % 211	
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serologically positive for B. caballi (n = 52). Overall EP seroprevalence was 8.0 % (n 212	
= 96), with 27.1 % of these (n = 26) being seropositive for both parasites. Theileria 213	
equi parasite DNA was detected in 0.8 % (n = 10) of the samples from these 214	
laboratory submissions. Sanger sequencing revealed that all nucleotide sequences 215	
detected had 97-100 % identity to the relevant section of the 18S SSU rRNA gene of 216	
T. equi. Babesia caballi DNA was not detected in any sample. 217	
The purpose of EP serology as stated on the submission form, and where permitted 218	
without breach of data confidentiality, is summarised in Table 2. Testing prior to 219	
potential export is highlighted as the predominant reason (81.5 % of submissions), 220	
with only a single animal for UK importation being tested. It is unknown what 221	
proportion of seropositive horses in the present dataset had previously been imported 222	
to the UK. Specific data regarding the testing purposes for the ‘other’ category were 223	
not available. 224	
In order to evaluate the sensitivity of EP serology, a comparison was made between 225	
those animals positive on nested PCR and serological status (see Table 3). Only four 226	
of the ten samples identified to have parasite DNA present were found to be 227	
seropositive, with variations between cELISA, CFT and IFAT test results. It was not 228	
possible to infer statistical agreement between the different test types, as not all 229	
samples were subjected to each test. 230	
The effect of sample submission type (coagulated versus anti-coagulated EDTA 231	
blood) on PCR test results is demonstrated in Figure 1, with samples from a 232	
confirmed UK case of EP submitted to the study. The affected horse (L1) in this case 233	
was imported several months previously and had developed clinical signs of anaemia 234	
and pyrexia, consistent with acute piroplasmosis. After positive cELISA and IFAT 235	
serology for EP from AHT, a blood sample was collected for PCR analysis. 236	
Importantly, both a clotted and an anti-coagulated (EDTA) jugular blood sample were 237	
collected at the same time and stored identically before submission. DNA extraction 238	
and nested PCR EP testing were performed concurrently and in triplicate on the 239	
submitted samples, and the results compared. The coagulated sample produced 240	
negative results in each case, whilst all three of the anti-coagulated sample replicates 241	
produced a strong band that was subsequently sequenced and confirmed to be T. equi 242	
in origin.  243	
 244	
Discussion 245	
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Within the 1,242 samples submitted to the UK diagnostic services during the period 246	
February to December 2016 from horses resident in the UK, the overall 247	
seroprevalence of EP was 8.0 %. Although there is sparse information regarding EP 248	
seroprevalence in northern Europe, this is in line with similar datasets from Holland 249	
(15) and Switzerland (25) with 4 % and 7.3 % seroprevalence reported in these 250	
countries, respectively. Additional PCR-RLB performed by Butler et al (15) on 251	
EDTA blood detected T. equi DNA in 1.6 % of samples and did not detect any B. 252	
caballi DNA. However, this is not directly comparable to the current study’s T. equi 253	
DNA detection rate of 0.8 % and absence of detectable B. caballi DNA, as the use of 254	
EDTA samples by Butler et al. (15) may have provided greater sensitivity. 255	
Additionally, the sampled equine populations are not directly comparable between 256	
these and the current study. Butler et al (15) performed a cross-sectional study of 300 257	
horses known to have been resident in the same location within Holland for at least 258	
one year. Sigg et al (25) reported that of their 689 sampled animals, 459 (66.6 %) 259	
were imported (having been brought to Switzerland up to five years prior to testing) 260	
and all of those had arrived from a European country. Seroprevalence was 8.5 % in 261	
these imported horses versus 4.8 % in indigenous horses (25). In both studies the 262	
previous movement history was limited or absent, making the geographical source of 263	
infection unclear. No geographical data or previous travel history was available for 264	
the current study samples due to data confidentiality. 265	
Within the set of seropositive samples identified in this study, 27.1 % were found to 266	
be positive for both T. equi and B. caballi. This may be representative of exposure or 267	
infection by both parasites or serological false-positives (26); cross-reactivity with B. 268	
caballi has been noted at low titres with CFT and IFAT using serum from 269	
experimental T. equi infections (27). Due to a lack of further sampling and the 270	
absence of B. caballi identification by PCR, further investigation of this finding is 271	
beyond the scope of this study. 272	
Discrepancies between IFAT, cELISA and nested PCR results have been reported in 273	
experimental infection (9), and this was noted in the present study. The discrepancies 274	
encountered were:  275	
i) Serologically negative, PCR positive samples. It is shown in Table 3 that 6 of the 10 276	
samples where T. equi DNA was detected had negative serology results. Conventional 277	
logic would suggest that a detectable level of parasite DNA should promote a 278	
detectable immune response. The absence of seroconversion in the presence of 279	
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parasite DNA could either be due to an early stage of infection or a fluctuating 280	
parasitaemia, where samples were taken at a time of parasite proliferation but before 281	
the rise of a detectable antibody titre. This anomaly has been noted in the early course 282	
of experimental infection (9), and there is indication that CFT may be more sensitive 283	
than other serological methods in these early stages of infection (28). Disease 284	
recrudescence in EP has been noted to occur at times of increased stress and 285	
immunosuppression, such as may occur with increased handling, transport, co-286	
infection and even lactation (29). This phenomenon results in parasitic multiplication 287	
and the development of clinical signs in previously disease-free carrier animals. 288	
Whilst recent movement may have resulted in parasite recrudescence in a proportion 289	
of the animals in this study, it is unlikely that all of them would have been free from 290	
detectable levels of antibodies because once established as carriers, animals 291	
seroconvert to EP (9). 292	
The discrepancy between test modalities may have resulted also from the intrinsic 293	
limitations of the serological testing. Serological tests can give false-negative results 294	
(26) and this incongruity has been observed in previous studies. One example is a 295	
recent Venezuelan study which found T. equi to have a much higher PCR prevalence 296	
(61.8 %) than seroprevalence (14.0 %) (30). Additionally, Bhoora et al (31) 297	
postulated that genetic variation of the EMA-1 antigen, on which the cELISA used by 298	
APHA and AHT is based, may have prevented the detection of some South African 299	
strains of T. equi using this diagnostic technique. 300	
ii) High-titre serologically positive, PCR negative results. It was anticipated that a 301	
high serological titre would be associated with the presence of circulating parasite 302	
DNA and a positive PCR result. However, this was not seen in 15 high-titre (≥ 1/640) 303	
IFAT positive samples that were evaluated (data not shown). Titre values for the 304	
cELISA were not available. A potential reason for this became evident following a 305	
private sample submission to the project from an imported horse (L1). This horse was 306	
undergoing veterinary evaluation following presentation with acute anaemia and 307	
pyrexia. Tested in triplicate, Figure 1 shows that template DNA derived from EDTA 308	
blood samples provided clear positive bands, while the clotted blood samples were 309	
consistently negative. The reasons for this may include the degradation or reduction 310	
of available parasite DNA within the clotted samples and transfer of inhibitors during 311	
DNA extraction. Regardless of the exact cause, this clearly demonstrates a significant 312	
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reduction in PCR sensitivity using clotted blood samples, although the full extent of 313	
this requires validation in additional cases. 314	
All PCR screening in this study was performed on clotted blood samples, using the 315	
residual sample following serological evaluation. These were the only diagnostic 316	
specimens available to the group in this instance. Given the evidence presented in 317	
Figure 1, if clotted blood samples cannot provide a repeatable PCR positive result for 318	
EP from a horse with active disease and acute clinical signs, then this has important 319	
implications for reported negative PCR results. Despite the screening data initially 320	
appearing consistent with results from comparable studies in other countries, the 321	
availability of primarily clotted blood samples in this study is likely to have 322	
significantly underestimated the number of T. equi PCR positive carrier animals in the 323	
sample set. This may also explain the complete absence of B. caballi detection by 324	
PCR despite serological detection among the samples. Consequently, we recommend 325	
avoiding the use of clotted blood samples for PCR screening. 326	
iii) Low-titre serologically positive, PCR negative samples. Typically these may 327	
simply represent previous disease exposure, though in the case of EP it could signify a 328	
latent carrier state that lacks sufficient circulating parasite for DNA detection. 329	
Alternatively, these could be serological false-positive results, an issue inherent with 330	
serological testing (26). However, given the apparent reduction of PCR sensitivity in 331	
this study, no further interpretation can be made on these samples. 332	
Another conspicuous finding of this study is the apparently low uptake of EP testing 333	
in horses in the UK following importation (Table 2). Strikingly, only a single sample 334	
of 1,097 submitted to APHA was for the purpose of determining EP status at time of 335	
importation to the UK, strongly suggesting that there is widespread lack of awareness 336	
or indifference to EP biosecurity within the UK veterinary and equine industries. The 337	
most common purpose cited for sample submission was pre-export testing. This 338	
implies that the main driver for EP screening is to meet mandatory requirements for 339	
foreign export and not clinical investigation, and highlights the more stringent EP 340	
biosecurity controls imposed by other non-endemic countries such as USA, Australia, 341	
New Zealand and Japan. 342	
In summary, this study shows that a small but important proportion of equids residing 343	
in the UK are seropositive for EP, and that parasite DNA is detectable in a further 344	
proportion of these. Given the diagnostic limitations imposed in this study, namely 345	
the use of remnant clotted material following serological testing, it is likely that 346	
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piroplasmosis DNA is present in a higher proportion of UK equids than reported here. 347	
As it is known that carriers of EP may undergo disease recrudescence at times of co-348	
infection, stress and immunosuppression, UK veterinary practitioners should be aware 349	
that EP should be a differential diagnosis for horses presenting with characteristic 350	
clinical signs in this country, which may include pyrexia, lethargy and evidence of 351	
haemolysis. 352	
Although a detailed distribution of EP vector tick species within the UK is not fully 353	
known, the presence of equids positive for parasite DNA in tick-infested pasture 354	
should be considered a potential risk for disease transmission to co-grazing equids, 355	
and this requires assessment. The authors note that the factors of reduced restrictions 356	
on international equine movement and an absence of any UK formal import screening 357	
for EP, coupled with the limitations of current testing methods, present a continued 358	
risk to the UK equine population and industry. This study suggests that a combined 359	
approach of serology and parasite DNA detection is required to provide the most 360	
efficacious EP screening protocol. It is also suggested that in the event of positive 361	
animals being identified in the UK, follow-up screening of co-grazing animals and 362	
ticks could be considered as a means of local and national disease surveillance. The 363	
authors believe that a change in attitude towards the disease and national EP 364	
biosecurity is required before endemic disease establishment creates a complex 365	
problem that is more difficult to resolve. 366	
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No. of 
samples 
  
T. equi serology (No. of 
positives/total no. of tests) 
 
  
  
T. equi 
PCR 
  
B. caballi serology (No. of 
positives/total no. of tests)  
  
  
  
B. caballi 
PCR 
  
CFT IFAT cELISA Total unique 
seropositives 
CFT IFAT cELISA Total unique 
seropositives 
APHA 1097 31/482 39/502 9/562 66/1050 6.3 % 7/1066 17/479 33/504 2/563 49/1049 4.7 % 0/1066 
AHT 145 NA 4/9 4/145 4/145 2.8 % 3/145 NA 1/9 2/145 3/145 2.1 % 0/145 
Total 1242 6.4 % 8.4 % 1.8 % 5.9 %   0.8 % 3.5 % 6.6 % 0.6 % 4.4 %   0 % 
Table 1. Breakdown by test type of EP positive results from samples screened between February and December 2016. The results are listed by 488	
submitting organisation and test type. As some samples were found to be positive by multiple serological methods; the ‘Total unique 489	
seropositives’ columns show the number of discrete positive samples for each species.  490	
	 19	
 Reason for EP testing  
Import Export Other Unknown 
APHA 1/1097 894/1097 189/1097 13/1097 
AHT NA NA NA 145/145 
Table 2. Reason for sample submission as noted by the submitting veterinary surgeon. Most samples were submitted prior to intended export, 491	
highlighting that some countries require EP serology status to be determined prior to granting an importation licence. Notably only one sample 492	
was specifically submitted to determine EP serological status at time of importation to the UK.  493	
	 20	
Samples positive by nested PCR 
ID Organisation CFT (T. equi) IFAT (T. equi) cELISA (T. equi) CFT (B. caballi) IFAT (B. caballi) cELISA (B. caballi) 
VLA12 APHA NA Negative NA NA Negative NA 
VLA14 APHA NA Negative NA NA Negative NA 
VLA15 APHA NA Negative NA NA Negative NA 
VLA255 APHA NA Positive NA NA Positive NA 
VLA265 APHA Positive Positive Positive Negative NA Negative 
VLA269 APHA NA NA Negative NA NA Negative 
VLA761 APHA Positive Negative Positive Positive Negative Negative 
AHT18 AHT NA Negative Negative NA Negative Negative 
AHT21 AHT NA Negative Negative NA Negative Negative 
L1 AHT NA Positive Positive NA Negative Negative 
Table 3. Serological data for samples found to be positive by nested PCR during the study. These samples were all positive for T. equi and 494	
negative for B. caballi on sequencing of the PCR product.  495	
	 21	
Figure 1. An electrophoresis gel showing the final PCR product from sample L1. The expected fragment length for T. equi was 433 bp. Template 496	
DNA was extracted from clotted blood samples (C1-3) and from EDTA samples (A1-3). Controls using DNA extracted from known EP positive 497	
(P) and EP negative (N) horse blood are shown together with a 100 bp ladder (L). 498	
 499	
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